Pharmaceutical

ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy

The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.

Sep 6, 2024 - 04:00
ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.
Read the original article

Tags:

Previous Article

ESC 2024: Insights into RNA as therapeutic target and tool

Next Article

Lilly partners with Haya for lncRNA obesity target deal worth $1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Roche records 4% decline in H1 2024 net income

Roche records 4% decline in H1 2024 net income

Jul 28, 2024

STAT+: Study finds supplements of amino acid taurine slow aging in mice and monkeys

STAT+: Study finds supplements of amino acid taurine sl...

Jun 8, 2023

STAT+: Major pharma companies call on their suppliers to reduce carbon footprints

STAT+: Major pharma companies call on their suppliers t...

Jul 22, 2023